



APRIL 2021

KMAP GENERAL BULLETIN 21064

Prior Authorization Process for Cancer Treatment - Auxiliary Agents

Effective May 1, 2021, auxiliary drugs for cancer treatment will be added to the list of drugs managed by the Managed Care Organizations (MCOs) oncology vendor prior authorization (PA) process. Applicable auxiliary drugs are listed under Oncology - Auxiliary Treatment Agents PA criteria found on the Kansas Department of Health and Environment (KDHE) [website](#).

The Fee-for-Service (FFS) fiscal agent will continue to use the Clinical PA criteria to determine PA approval or denial.

All previous MCO contract requirements to follow the State PA criteria and forms still apply, except the Oncology Treatment PA and Oncology Treatment-Auxiliary Agents PA approved by the Drug Utilization Review (DUR) board.

Note: The effective date of the policy is May 1, 2021. The implementation of State policy by the KanCare Managed Care Organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The **KanCare Open Claims Resolution Log** on the KMAP [Bulletins](#) page documents the MCO system status for policy implementation and any associated reprocessing completion dates, once the policy is implemented.

KMAP

[Kansas Medical Assistance Program](#)

- [Bulletins](#)
- [Manuals](#)
- [Forms](#)

Customer Service

- 1-800-933-6593
- 7:30 a.m. - 5:30 p.m.
Monday - Friday

Gainwell Technologies is the fiscal agent for KMAP